Effect of the Intensity of Continuous Renal Replacement Therapy
1 other identifier
interventional
280
1 country
1
Brief Summary
In patients with sepsis and AKI, increasing the intensity of renal replacement therapy from 50 mL/kg/h (HVHF) to 85 mL/kg/h (EHVHF)will increase the survival at 28 days and 90 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2004
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedFirst Submitted
Initial submission to the registry
November 30, 2010
CompletedFirst Posted
Study publicly available on registry
December 1, 2010
CompletedDecember 1, 2010
January 1, 2004
5.6 years
November 30, 2010
November 30, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
90 days survival
The primary study outcome was death from any cause within 90 days. Results were analyzed by Kaplan-Meier survival curves
Secondary Outcomes (1)
length of stay in the ICU and hospital
Study Arms (2)
extra high volume hemofiltration
EXPERIMENTALextra high volume hemofiltration (85 mL/kg/h, EHVHF)
high volume hemofiltration
SHAM COMPARATORhigh volume hemofiltration (50 mL/kg/h, HVHF)
Interventions
extra high volume hemofiltration (85 mL/kg/h, EHVHF)
high volume hemofiltration (50 mL/kg/h, HVHF)
Eligibility Criteria
You may qualify if:
- met at least one of the following criteria: oliguria (urine output less than 100 mL in a 6 h period and unresponsive to fluid resuscitation), serum potassium concentration more than 6.5 mmol/L, severe acidemia (pH \< 7.2), serum creatinine more than 250 µmol/L, or presence of severe organ edema (e.g. pulmonary edema).
You may not qualify if:
- were presence of a malignant tumor, chronic renal insufficiency (serum creatinine \>133 µmol/L), or receiving any kind of renal replacement therapy before randomization.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kidney disease center, the first affiliated hospital, medical college of Zhejiang university
Hangzhou, Zhejiang, 310003, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
jianghua chen, MD
Kidney disease center, the first affiliated hospital, medical college of Zhejiang university
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Purpose
- TREATMENT
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 30, 2010
First Posted
December 1, 2010
Study Start
January 1, 2004
Primary Completion
August 1, 2009
Study Completion
June 1, 2010
Last Updated
December 1, 2010
Record last verified: 2004-01